
Before New Year's, the bar will be raised for how well a diabetes drug can perform when Eli Lilly displays the first phase III results from the future hope tirzepatide.
That is, at least, the hope that Eli Lilly's Global Brand Development Leader James Croaning has. He is in charge of the development of tirzepatide in Eli Lilly's diabetes business.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app